[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[3] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[4] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[5] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[6] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[7] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[8] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[9] |
CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming.
Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
|
[10] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[11] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[12] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[13] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[14] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[15] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|